ACRS (Aclaris Therapeutics) Tariff Resilience Score: 5/10 (As of Jul. 02, 2026)


ACRS Aclaris Therapeutics Inc ACRS
38 GF Score
Price $5.33
GF Value $0.45
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Aclaris Therapeutics Tariff Resilience Score?

Aclaris Therapeutics ACRS +0.95% 38 Tariff Resilience Score is 5 as of Jul. 02, 2026. GuruFocus rates ACRS with a GF Score™ of 38/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,374 Biotechnology companies, Aclaris Therapeutics ranks better than 62.23% on this metric.

Aclaris Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Aclaris Therapeutics has Aclaris Therapeutics Inc faces moderate tariff exposure due to its reliance on imported pharmaceutical ingredients. However, its primary market is domestic, and it has some ability to pass costs to consumers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Aclaris Therapeutics might have Average Resilient.

Aclaris Therapeutics  (NAS:ACRS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Aclaris Therapeutics Tariff Resilience Score Related Terms

ACRS vs RLMD, GYRE, SGP: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Aclaris Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aclaris Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Tariff Resilience Score falls into.


ACRS
38GF Score
Aclaris Therapeutics Inc ACRS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Aclaris Therapeutics (ACRS) has a Tariff Resilience Score of 5 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Aclaris Therapeutics ranks #519 out of 1374 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Aclaris Therapeutics' Tariff Resilience Score too high?
Aclaris Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Aclaris Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Aclaris Therapeutics ranks #519 out of 1374 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' Tariff Resilience Score compare to RLMD and GYRE?
According to the Biotechnology industry distribution chart, Aclaris Therapeutics ranks #519 out of 1374 companies for Tariff Resilience Score. This puts Aclaris Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Aclaris Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aclaris Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aclaris Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $5.33 — trading 1084.4% above its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Aclaris Therapeutics' overall GF Score™ is 38/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current Tariff Resilience Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aclaris Therapeutics (ACRS) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of $5.33 is trading 1084.4% above its estimated GF Value™ of $0.45. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for ACRS:

  • Tariff Resilience Score: 5
  • GF Value™: $0.45 vs. price of $5.33 (1084.4% above fair value)
  • GF Score™: 38/100 with 10 warning signs
  • Industry Position: 25% above the Biotechnology median (#519 of 1374)

No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aclaris Therapeutics Business Description

Other Exchanges 0H8T:UK8AT:Germany
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
38GF Score

Get the complete analysis for ACRS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.33
Price
$0.45
GF Value